Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United States

被引:42
作者
Kavcic, Marko [1 ]
Fisher, Brian T. [2 ,3 ,4 ]
Seif, Alix E. [1 ,4 ]
Li, Yimei [1 ]
Huang, Yuan-Shung [4 ]
Walker, Dana [1 ,4 ]
Aplenc, Richard [1 ,3 ,4 ,5 ]
机构
[1] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
RHEUMATOID-ARTHRITIS; B-CELLS; SAFETY; CHILDHOOD; LYMPHOMA; THERAPY;
D O I
10.1016/j.jpeds.2012.11.038
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To describe the pharmacoepidemiology of rituximab use in children and to estimate the frequency of infectious events within a 1-year period after rituximab exposure. Study design This is a retrospective cohort study of patients who received rituximab at 1 of 42 children's hospitals contributing data to the Pediatric Health Information System between January 1999 and June 2011. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnosis codes were analyzed to categorize underlying diseases (hematologic malignancies, primary immunodeficiencies, autoimmune diseases, and transplant recipients) and to estimate inpatient infectious complication rates within each category. Results A total of 2875 patients with 4639 rituximab admissions were identified. The median age at index admission was 11 years (IQR, 5-15 years). The rate of rituximab admissions increased from 3 to 185 per 100 000 admissions per year over the study interval. During the 1-year follow-up period, 463 patients (16%) died. Infectious events were assessed in 2246 of the rituximab-exposed patients; 6.1% were diagnosed with sepsis and 2.0% with septic shock. The frequency of sepsis ranged from 2.4% in patients with autoimmune diseases to 12.2% in those with primary immunodeficiencies. Three patients were assigned an ICD-9-CM discharge diagnosis code for Pneumocystis joroveci pneumonia, 1 patient was assigned an ICD-9-CM discharge diagnosis code for hepatitis B, and 1 patient was assigned an ICD-9-CM discharge diagnosis code for progressive multifocal leukoencephalopathy. Conclusion The use of rituximab has increased significantly in children with a variety of underlying diseases. Based on ICD-9-CM code data, the rates of sepsis and other life-threatening infections after rituximab exposure vary depending on the underlying condition. Based on surveillance of infection using ICD-9-CM diagnosis codes, the rates of opportunistic infections appear to be low.
引用
收藏
页码:1252 / U226
页数:8
相关论文
共 22 条
[1]   Rituximab-related viral infections in lymphoma patients [J].
Aksoy, Sercan ;
Harputluoglu, Hakan ;
Kilickap, Saadettin ;
Dede, Didem Sener ;
Dizdar, Omer ;
Altundag, Kadri ;
Barista, Ibrahim .
LEUKEMIA & LYMPHOMA, 2007, 48 (07) :1307-1312
[2]   Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura [J].
Bennett, CM ;
Rogers, ZR ;
Kinnamon, DD ;
Bussel, JB ;
Mahoney, DH ;
Abshire, TC ;
Sawaf, H ;
Moore, TB ;
Loh, ML ;
Glader, BE ;
McCarthy, MC ;
Mueller, BU ;
Olson, TA ;
Lorenzana, AN ;
Mentzer, WC ;
Buchanan, GR ;
Feldman, HA ;
Neufeld, EJ .
BLOOD, 2006, 107 (07) :2639-2642
[3]   Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project [J].
Carson, Kenneth R. ;
Evens, Andrew M. ;
Richey, Elizabeth A. ;
Habermann, Thomas M. ;
Focosi, Daniele ;
Seymour, John F. ;
Laubach, Jacob ;
Bawn, Susie D. ;
Gordon, Leo I. ;
Winter, Jane N. ;
Furman, Richard R. ;
Vose, Julie M. ;
Zelenetz, Andrew D. ;
Mamtani, Ronac ;
Raisch, Dennis W. ;
Dorshimer, Gary W. ;
Rosen, Steven T. ;
Muro, Kenji ;
Gottardi-Littell, Numa R. ;
Talley, Robert L. ;
Sartor, Oliver ;
Green, David ;
Major, Eugene O. ;
Bennett, Charles L. .
BLOOD, 2009, 113 (20) :4834-4840
[4]   Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments [J].
Cattaneo, Chiara ;
Spedini, Pierangelo ;
Casari, Salvatore ;
Re, Alessandro ;
Tucci, Alessandra ;
Borlenghi, Erika ;
Ungari, Marco ;
Ruggeri, Giulia ;
Rossi, Giuseppe .
LEUKEMIA & LYMPHOMA, 2006, 47 (06) :1013-1017
[5]   Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases [J].
El-Hallak, Moussa ;
Binstadt, Bryce A. ;
Leichtner, Alan M. ;
Bennett, Carolyn M. ;
Neufeld, Ellis J. ;
Fuhlbrigge, Robert C. ;
Zurakowski, David ;
Sundel, Robert P. .
JOURNAL OF PEDIATRICS, 2007, 150 (04) :376-382
[6]   Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients [J].
Grim, Shellee A. ;
Pham, Thuy ;
Thielke, James ;
Sankary, Howard ;
Oberholzer, Jose ;
Benedetti, Enrico ;
Clark, Nina M. .
CLINICAL TRANSPLANTATION, 2007, 21 (05) :628-632
[7]   Pneumocystis jiroveci Pneumonia Following Rituximab Treatment in Wegener's Granulomatosis [J].
Hugle, Boris ;
Solomon, Melinda ;
Harvey, Elizabeth ;
James, Adrian ;
Wadhwa, Anupma ;
Amin, Reshma ;
Bell-Peter, Audrey ;
Benseler, Susanne .
ARTHRITIS CARE & RESEARCH, 2010, 62 (11) :1661-1664
[8]   Does rituximab increase the incidence of infectious complications? A narrative review [J].
Kelesidis, Theodoros ;
Daikos, George ;
Boumpas, Dimitrios ;
Tsiodras, Sotirios .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (01) :E2-E16
[9]   Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis [J].
Keystone, Edward ;
Fleischmann, Roy ;
Emery, Paul ;
Furst, Daniel E. ;
van Vollenhoven, Ronald ;
Bathon, Joan ;
Dougados, Maxime ;
Baldassare, Andrew ;
Ferraccioli, Gianfranco ;
Chubick, Andrew ;
Udell, James ;
Cravets, Matthew W. ;
Agarwal, Sunil ;
Cooper, Simon ;
Magrini, Fabio .
ARTHRITIS AND RHEUMATISM, 2007, 56 (12) :3896-3908
[10]   In Vivo Sensitized and In Vitro Activated B Cells Mediate Tumor Regression in Cancer Adoptive Immunotherapy [J].
Li, Qiao ;
Teitz-Tennenbaum, Seagal ;
Donald, Elizabeth J. ;
Li, Mu ;
Chang, Alfred E. .
JOURNAL OF IMMUNOLOGY, 2009, 183 (05) :3195-3203